Multiple sclerosis in the Shetlands, with an evaluation of Lioresal.
D000613:Aminobutyrates / Q000009:adverse effects / Q000627:therapeutic use*; D002722:Chlorobenzenes / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005006:Ethnicity; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000453:epidemiology; D009128:Muscle Spasticity / Q000188:drug therapy; D010276:Parasympatholytics / Q000009:adverse effects / Q000627:therapeutic use*; D006113:United Kingdom
D000613:Aminobutyrates; D002722:Chlorobenzenes; D010276:Parasympatholytics